Verapamil sustained release: New formulation and convolution

Pharmaceutical Development and Technology

Volumn 17, Issue 2, 2012, Pages 148-157

  Nguyen, Chien ^a   Christensen, J Mark ^b   Ayres, James W ^b  

^a HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Beads filled in a capsule; Lactose; Surelease ; Verapamil

Indexed keywords

ETHYL CELLULOSE; LACTOSE; STARCH GLYCOLATE SODIUM; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BEAD FORMULATION; BIOEQUIVALENCE; CAPSULE FILLING; DRUG CAPSULE; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; MAXIMUM PLASMA CONCENTRATION; PH; PRIORITY JOURNAL; SIMULATION; SPHERONIZATION; THICKNESS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTI-ARRHYTHMIA AGENTS; CELLULOSE; DELAYED-ACTION PREPARATIONS; KINETICS; LACTOSE; SOLUBILITY; VERAPAMIL;

EID: 84857404267     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.522582     Document Type: Article

References (15)

1. Ozturk AG, Ozturk SS, Palsson BO, Wheatley TA, Dressman JB. Mechanism of release from pellets coated with an ethylcellulosebased film. J Controlled Release 1990;14(3):203-213.
2. Bodmeier R. Tableting of coated pellets. Eur J Pharmaceut Biopharmaceut 1997;43:1-8.
3. El-Gazayerly ON, Rakkanka V, Ayres JW. Novel chewable sustained-release tablet containing verapamil hydrochloride. Pharmaceut Develop Technol 2004;9(2):181-188.
4. Vergote GJ, Kiekens F, Vervaet C, Remon JP. Wax beads as binder/ disintegrant agents during the compression of coated diltiazem pellets. Eur J Pharmaceut Sci 2002;17(3):145-151.
5. Sadeghi F, Ford JL, Rajabi-Siahboomi A. The influence of drug type on the release profiles from Surelease®-coated pellets. Int J Pharmaceut 2003;254(2):123-135.
6. Shah NH, Zhang L, Railkar A, Trivedi I, Patel CI, Infeld MH, Malick AW, Wong LK. Factors affecting the kinetics and mechanism of release of cilazapril from beadlets coated with aqueous and nonaqueous ethylcellulose-based coatings. Pharmaceut Technol 1994;18(10):140,142,144,146,148-149.
7. Arwidsson H, Hjelstuen O, Ingason D, Graffner C, Astra Laekemedel AB. Properties of ethylcellulose films for extended release. III. Influence of process factors when using aqueous dispersions. Acta Pharmaceut Nordica 1991;3(4):223-8.
8. Dressman JB, Derbin GM, Ismailos G, Jarvis C, Ozturk A, Palsson BO, Wheatley TA. Circumvention of pH-dependent release from ethylcellulose-coated pellets. J Controlled Release 1995;36(3):251-260.
9. Panoz DE, Tuckerstown BM, Geoghegan EJ, Westmeath IE. Controlled absorption pharmaceutical composition. United States Patent, 4,863,742; 1989.
10. McAllister Jr, Kirsten EB. The pharmacology of Verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Therapeut 1982;31:418-426.
11. Bechard SRRJ Jr, Leroux JC. Coated pelletized dosage form: Effect of compaction on drug release. Drug Develop Industrial Pharm 1992;18(18):1927-1944.
12. Altaf SA, Hoag SW, Ayres JW. Bead compacts. I. Effect of compression on maintenance of polymer coat integrity in multilayered bead formulations. Drug Develop Industrial Pharm 1998;24(8):737-746.
13. Ragnarsson G, Johansson MO. Coated drug cores in multiple unit preparations, influence of particle size. Drug Develop Industrial Pharm 1988;14(15-17):2285-2297.
14. Cutie MR, Lordi NG. Compatibility of verapamil hydrochloride injection in commonly used large-volume parenterals. Am J Hospital Pharm 1980;37(5):675-676.
15. Das Gupta V. Quantitation and stability of verapamil hydrochloride using high-performance liquid chromatography. Drug Develop Industrial Pharm 1985;11(8):1497-1506.